Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare disease where there is an unmet medical need. They have two areas of focus: a specialized biotherapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous T-cell lymphoma, oral mucositis, pediatric Crohn’s disease, and psoriasis. Also, a public health solutions segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, emerging and antibiotic resistant infectious disease, and viral disease including Ebola, Marburg and COVID-19.